An antibody conjugate, Ujvira combines the cancer cell growth–fighting properties of trastuzumab with the cytotoxic capability of emtansine.
Zydus Cadila, an Ahmedabad, India–based pharmaceutical company, said it has launched the world’s first biosimilar form of trastuzumab emtansine, an antibody drug conjugate that not only counteracts cancer cell growth (trastuzumab) but also delivers a cytotoxic agent to the cancer cell and helps to destroy it.
Zydus Cadila said the biosimilar (Ujvira) will be available on the Indian market and can be of value in treating human epidermal growth factor receptor 2 (HER2)-positive breast cancer, which is highly aggressive and constitutes 20% to 25% of all breast cancers.
“We hope that with this innovation, patients will be able to adhere to the treatment and stand to benefit from the advanced technology without worrying about the cost of the treatment,” said Sharvil Patel, managing director of Cadila Healthcare, in a statement. An estimated 1 in 29 women in India are at risk of developing breast cancer.
In some forms of breast cancer, HER2 receptors are overexpressed on the cancer cell. These receptors receive signals that stimulate the cell to grow and multiply. Trastuzumab attaches to the receptors and blocks the signaling process, causing growth of the cancer cells to stop. Trastuzumab can also alert the immune system to destroy cancer cells.
When trastuzumab attaches to the HER2 receptor, emtansine is able to enter the cancer cell and kill it. The originator trastuzumab emtansine (Kadcycla) was developed by Genentech, a subsidiary of Roche. Zydus Cadila said it would market the biosimilar version “at nearly 80% less than” the originator product.
Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth
March 14th 2024In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Filgrastim Biosimilars in Europe: 15 Years of Real-World Evidence for Zarxio
March 13th 2024A review looking back at the last 15 years of experience with the first filgrastim biosimilar (Zarxio) provides a detailed overview on how filgrastim biosimilars came to be and the evidence behind why oncologists have come to accept them as standard practice.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
The Role of Biosimilars: Advancing Access, Financial Health, and System Sustainability
March 11th 2024Kashyap Patel, MD, CEO of Carolina Blood and Cancer Care, a member of the Community Oncology Alliance, and member of The Center for Biosimilars® Advisory Board, glances back at the development of the biosimilar industry and the last 5 years of progress.